Abstract: A picture generation apparatus and a control method thereof are disclosed. An embodiment of the present disclosure provides a picture generation apparatus including a light source; a Spatial Light Modulator (SLM) configured to output an image using light transmitted from the light source; and a control unit configured to control the light source and the SLM based on at least one of illuminance of the surroundings or content of the image.

Abstract: According to at least one aspect, the present disclosure provides a vehicle head-up display apparatus comprising: a lower case; an aspherical mirror including spherical mounts formed at both ends of the aspherical mirror; a plurality of reception blocks included in the lower case to seat the spherical mounts so that the aspherical mirror is rotatable, and formed to have a shape corresponding to each spherical mount so that a clearance with the spherical mount does not occur; at least one mount fixing unit surrounding at least a portion of the spherical mount in a state where the spherical mount is seated on each of the plurality of reception blocks to limit a displacement of the spherical mount by a predetermined fixing force; and a screen including a coupling hole for coupling with the mount fixing unit and coupled to the lower case.

Abstract: The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R1 and R2 are independently H— or alkyl; R3 is H—, alkyl or aralkyl; and R4 is H— or aryl.

Abstract: Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.

Abstract: Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.

Abstract: The present invention relates to a use for the purpose of preventing, alleviating, or treating bipolar disorder by administering a pharmaceutical composition comprising a carbamate compound of the following chemical formula 1.

Abstract: A vehicle head-up display apparatus and manufacturing method thereof are disclosed. The present disclosure in some embodiments provides a vehicle head-up display apparatus including a lower case, an aspherical mirror, a plurality of plate springs, and a screen. The aspherical mirror has opposite ends respectively formed with spherical mounts that rotatably attach the aspherical mirror to the lower case. Each of the plate springs are respectively positioned above one of the spherical mounts to limit displacements of the spherical mounts. The screen includes at least one or more combining holes configured to be coupled with the plate springs and is configured to be coupled with the lower case. Here, the lower case includes a plurality of reception blocks configured to seat the spherical mounts from underneath and formed in a shape conformable to the spherical mounts to allow no clearance against the spherical mounts.

Abstract: According to at least one aspect, the present disclosure provides a vehicle head-up display apparatus comprising: a lower case; an aspherical mirror including spherical mounts formed at both ends of the aspherical mirror; a plurality of reception blocks included in the lower case to seat the spherical mounts so that the aspherical mirror is rotatable, and formed to have a shape corresponding to each spherical mount so that a clearance with the spherical mount does not occur; at least one mount fixing unit surrounding at least a portion of the spherical mount in a state where the spherical mount is seated on each of the plurality of reception blocks to limit a displacement of the spherical mount by a predetermined fixing force; and a screen including a coupling hole for coupling with the mount fixing unit and coupled to the lower case.

Abstract: Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.

Abstract: A vehicle head-up display apparatus and manufacturing method thereof are disclosed. The present disclosure in some embodiments provides a vehicle head-up display apparatus including a lower case, an aspherical mirror, a plurality of plate springs, and a screen. The aspherical mirror has opposite ends respectively formed with spherical mounts that rotatably attach the aspherical mirror to the lower case. Each of the plate springs are respectively positioned above one of the spherical mounts to limit displacements of the spherical mounts. The screen includes at least one or more combining holes configured to be coupled with the plate springs and is configured to be coupled with the lower case. Here, the lower case includes a plurality of reception blocks configured to seat the spherical mounts from underneath and formed in a shape conformable to the spherical mounts to allow no clearance against the spherical mounts.

Abstract: The present invention relates to a use for the purpose of preventing, alleviating, or treating status epilepticus by administering a medicament or pharmaceutical composition comprising a carbamate compound of chemical formula 1.

Abstract: Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.

Abstract: Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.

Abstract: The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R1 and R2 are independently H— or alkyl; R3 is H—, alkyl or aralkyl; and R4 is H— or aryl.

Abstract: The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R1 and R2 are independently H— or alkyl; R3 is H—, alkyl or aralkyl; and R4 is H— or aryl.

Abstract: An HUD apparatus for a vehicle including: a housing mounted in a vehicle; a cover member configured to open/close the entrance of the housing; a combiner operated separately from the cover member, and protruding outward from the inside of the housing; a rotating cam rotatably installed in the housing, rotated by rotation power, and having guide grooves; a first gear member having one side connected to the cover member and the other part inserted into the guide groove, and operated by rotation of the rotating cam so as to move the cover member; and a second gear member having one side connected to the combiner and the other side inserted into the guide groove, and operated by the rotation of the rotating cam so as to move the combiner to the outside or inside of the housing.

Abstract: The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R1 and R2 are independently H— or alkyl; R3 is H—, alkyl or aralkyl; and R4 is H— or aryl.

Abstract: The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R1 and R2 are independently H— or alkyl; R3 is H—, alkyl or aralkyl; and R4 is H— or aryl.

Abstract: The present invention relates to a use for the purpose of preventing, alleviating, or treating bipolar disorder by administering a pharmaceutical composition comprising a carbamate compound of the following chemical formula 1.

Abstract: The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R1 and R2 are independently H— or alkyl; R3 is H—, alkyl or aralkyl; and R4 is H— or aryl.